Loading clinical trials...

Raloxifene Use for The Heart | Clinical Trials | Clareo Health

COMPLETEDPHASE3

Raloxifene Use for The Heart

Raloxifene Hydrochloride or Placebo in Postmenopausal Women at Risk for Major Coronary Events

NCT00190593•Eli Lilly and Company

Summary

The purpose of this study is to determine whether raloxifene compared with placebo lowers the risk of coronary events and reduces the risk of invasive breast cancer in postmenopausal women at risk for major coronary events.

Eligibility

Age

55 - No limit years

Sex

FEMALE

Healthy Volunteers

Inclusion Criteria

•Postmenopausal women with established coronary heart disease or at risk for a major coronary event.

Exclusion Criteria

•Postmenopausal symptoms that required estrogen replacement therapy.
•Suspected or known history of breast or endometrial carcinoma.
•Known or probable history of deep venous thrombosis, pulmonary embolism, or retinal vein thrombosis.
•New York Heart Association classes III or IV heart failure.

Locations (1)

For additonal information regarding investigative sites for this trial, please call 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559), Monday-Friday, 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician

Minneapolis, Minnesota, United States

Key Dates

Start Date

June 1, 1998

Completion Date

November 1, 2005

Last Updated

January 26, 2007

Enrollment

10,000

Estimated participants

Conditions

Cardiovascular DiseasesBreast Neoplasms

Interventions

raloxifene

DRUG

placebo

DRUG

ML Score Prediction of Cardiotoxicity in Cancer Patients Receiving Anthracycline Chemotherapy or HER2-Targeted Therapies

NCT07191730

CardiotoxicityHeart Failure+2 more

View study

RECRUITINGNA

The Prevalence, Disease Burden and Prognosis of COPD in Patients With Cardiovascular Diseases

NCT06909773

Cardiovascular Diseases

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 26, 2007Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Raloxifene Use for The Heart

Inclusion Criteria

Exclusion Criteria

ML Score Prediction of Cardiotoxicity in Cancer Patients Receiving Anthracycline Chemotherapy or HER2-Targeted Therapies

The Prevalence, Disease Burden and Prognosis of COPD in Patients With Cardiovascular Diseases

OPTImizing CArdiac REhabilitation by REfining Sleep and STress

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

Evaluation of Clinical Efficacy of Augmented Reality (AR)-Based Breast Cancer Medical Imaging Solution (SKIA-Breast) Localization Method in Breast Cancer Patients